

Neoadjuvant treatment of pancreatic adenocarcinoma: meta-analysis of 5520 patients

World Journal of Surgical Oncology

15, 183

DOI: [10.1186/s12957-017-1240-2](https://doi.org/10.1186/s12957-017-1240-2)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Shifting the treatment model for resectable pancreatic cancer. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 375-376.	3.7	1
2	Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?. <i>Clinical Cancer Research</i> , 2018, 24, 2241-2250.	3.2	32
3	Predictive Early Recurrence Factors of Preoperative Clinicophysiological Findings in Pancreatic Cancer. <i>European Surgical Research</i> , 2018, 59, 329-338.	0.6	21
4	A Glimmer of Hope for Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2463-2464.	13.9	39
5	ASO Author Reflections: Neoadjuvant Treatment of Resectable and Borderline-Resectable Pancreatic Head Adenocarcinoma: Is FOLFIRINOX Better than Gem/Nab-Paclitaxel?. <i>Annals of Surgical Oncology</i> , 2018, 25, 808-809.	0.7	6
6	The Role of Neoadjuvant Therapy in Surgical Treatment of Pancreatic Cancer. , 2018, , .		0
7	FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 1896-1903.	0.7	88
8	Pathology assessment of pancreatic cancer following neoadjuvant treatment: Time to move on. <i>Pancreatology</i> , 2018, 18, 467-476.	0.5	57
9	Radiological assessment of local resectability status in patients with pancreatic cancer: Interreader agreement and reader performance in two different classification systems. <i>European Journal of Radiology</i> , 2018, 106, 69-76.	1.2	5
10	The Impact of Hospital Neoadjuvant Therapy Utilization on Survival Outcomes for Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 2661-2668.	0.7	7
11	Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma. <i>Radiation Oncology</i> , 2019, 14, 120.	1.2	16
12	An update on treatment options for pancreatic adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987556.	1.4	144
13	Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis. <i>Scientific Reports</i> , 2019, 9, 15662.	1.6	38
14	Endoscopic ultrasound-guided biliary drainage for distal malignant obstruction: a systematic review and meta-analysis of randomized trials. <i>Endoscopy International Open</i> , 2019, 07, E1563-E1573.	0.9	39
15	Clinical usefulness of conversion surgery for unresectable pancreatic cancer diagnosed on multidetector computed tomography imaging: Results from a multicenter observational cohort study by the Hokkaido Pancreatic Cancer Study Group (HOPS URâ€œ01). <i>Annals of Gastroenterological Surgery</i> , 2019, 3, 523-533.	1.2	13
17	A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 4498-4505.	0.7	34
18	Role of surgical resection in the era of <sc>FOLFIRINOX</sc> for advanced pancreatic cancer. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2019, 26, 416-425.	1.4	33
19	Contemporary management of borderline resectable pancreatic ductal adenocarcinoma. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2019, 23, 97.	0.1	15

#	ARTICLE	IF	CITATIONS
20	Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma. <i>Acta Oncologica</i> , 2019, 58, 1259-1266.	0.8	19
21	Imaging response evaluation after novel neoadjuvant treatments of pancreatic cancer. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2019, 51, 146-152.	0.3	7
22	Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation. <i>American Journal of Surgical Pathology</i> , 2019, 43, 334-340.	2.1	19
24	Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1674-1683.	0.5	62
25	Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club. <i>Przeład Gastroenterologiczny</i> , 2019, 14, 1-18.	0.3	64
26	Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues. <i>Surgery Today</i> , 2019, 49, 894-906.	0.7	25
27	Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma. <i>Digestive Surgery</i> , 2019, 36, 455-461.	0.6	26
29	Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 112-121.	0.9	54
30	Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2019, 269, 1154-1162.	2.1	222
31	Circulating Tumor Cells are an Independent Predictor of Shorter Survival in Patients Undergoing Resection for Pancreatic and Periampullary Adenocarcinoma. <i>Annals of Surgery</i> , 2020, 271, 549-558.	2.1	40
32	National Use of Chemotherapy in Initial Management of Stage I Pancreatic Cancer and Failure to Perform Subsequent Resection. <i>Annals of Surgical Oncology</i> , 2020, 27, 909-918.	0.7	6
33	SMAD4-Expressing Pancreatic Ductal Adenocarcinomas Have Better Response to Neoadjuvant Therapy and Significantly Lower Lymph Node Metastasis Rates. <i>Pancreas</i> , 2020, 49, 1153-1160.	0.5	5
34	Comprehensive comparison of clinicopathological characteristics, treatment, and prognosis of borderline resectable pancreatic cancer according to tumor location. <i>Pancreatology</i> , 2020, 20, 1123-1130.	0.5	10
35	Novel risk factors for recurrent biliary obstruction and pancreatitis after metallic stent placement in pancreatic cancer. <i>Endoscopy International Open</i> , 2020, 08, E1603-E1610.	0.9	10
36	Treatment Strategies for the Optimal Management of Locally Advanced Pancreatic Adenocarcinoma With Curative Intent. <i>Pancreas</i> , 2020, 49, 1264-1275.	0.5	5
37	Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1461.	1.3	2
38	A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094796.	1.4	9
39	Intraoperative electrochemotherapy in locally advanced pancreatic cancer: indications, techniques and results—a single-center experience. <i>Updates in Surgery</i> , 2020, 72, 1089-1096.	0.9	16

#	ARTICLE	IF	CITATIONS
40	The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis. <i>BMC Cancer</i> , 2020, 20, 538.	1.1	8
41	Neoadjuvant or Adjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer: Which Is Preferred?. <i>Journal of Clinical Oncology</i> , 2020, 38, 1757-1759.	0.8	19
42	Open and Minimal Approaches to Pancreatic Adenocarcinoma. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-12.	0.7	2
43	Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation. <i>Histopathology</i> , 2020, 77, 35-45.	1.6	9
44	Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 41.	1.3	68
45	Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol?. <i>Annals of Gastroenterological Surgery</i> , 2020, 4, 100-108.	1.2	35
46	Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma. <i>Molecular Cancer</i> , 2020, 19, 32.	7.9	124
47	Predictors of Disease Progression or Performance Status Decline in Patients Undergoing Neoadjuvant Therapy for Localized Pancreatic Head Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 2961-2971.	0.7	8
48	Important CT and histopathological findings for recurrence and overall survival in patients with pancreatic ductal adenocarcinoma who underwent surgery after neoadjuvant FOLFIRINOX. <i>European Radiology</i> , 2021, 31, 3616-3626.	2.3	4
49	Predicting Positive Margins in Pancreatic Head Adenocarcinoma After Neoadjuvant Therapy: Investigating Disparities in Quality Care Using the National Cancer Database. <i>Annals of Surgical Oncology</i> , 2021, 28, 1595-1601.	0.7	5
50	Radiologic Evaluation for Resectability of Pancreatic Adenocarcinoma. <i>Journal of the Korean Society of Radiology</i> , 2021, 82, 315.	0.1	0
51	Prognostic analysis of pancreatic carcinoma with portal system invasion following curative resection. <i>Gland Surgery</i> , 2021, 10, 35-49.	0.5	7
52	Survival equivalence in patients treated for borderline resectable and unresectable locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis. <i>Hpb</i> , 2021, 23, 173-186.	0.1	7
53	Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma. <i>JAMA Oncology</i> , 2021, 7, 421.	3.4	159
54	Diagnosis of Pancreatic Ductal Adenocarcinoma by Immuno-Positron Emission Tomography. <i>Journal of Clinical Medicine</i> , 2021, 10, 1151.	1.0	8
55	Four-Tier Pathologic Tumor Regression Grading System Predicts the Clinical Outcome in Patients Who Undergo Surgical Resection for Locally Advanced Pancreatic Cancer after Neoadjuvant Chemotherapy. <i>Gut and Liver</i> , 2022, 16, 129-137.	1.4	2
56	The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies. <i>Biomedicines</i> , 2021, 9, 389.	1.4	21
57	Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX. <i>Gut and Liver</i> , 2021, 15, 466-475.	1.4	11

#	ARTICLE	IF	CITATIONS
58	Contemporary Reappraisal of Intraoperative Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2021, 156, 489.	2.2	8
59	Which patients benefit from preoperative biliary drainage in resectable pancreatic cancer?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 855-863.	1.4	5
60	Head-to-head comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel in the neoadjuvant chemotherapy of localized pancreatic cancer: a systematic review and meta-analysis. <i>Gland Surgery</i> , 2021, 10, 1564-1575.	0.5	10
61	Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2021, 25, 179-191.	0.1	9
62	Feasibility and efficacy of a multicomponent exercise medicine programme in patients with pancreatic cancer undergoing neoadjuvant therapy (the EXPAN trial): study protocol of a dual-centre, two-armed phase I randomised controlled trial. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000642.	1.1	3
63	Borderline resectable pancreatic cancer: Certainties and controversies. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 516-528.	0.8	6
64	Predictors of conversion surgery in patients with pancreatic cancer who underwent neoadjuvant or palliative FOLFIRINOX treatment using baseline and follow-up CT. <i>Abdominal Radiology</i> , 2021, 46, 4765-4778.	1.0	2
65	Perception versus reality: A National Cohort Analysis of the surgeryâ€™s first approach for resectable pancreatic cancer. <i>Cancer Medicine</i> , 2021, 10, 5925-5935.	1.3	3
66	Optimal management of patients with operable pancreatic head cancer: A Markov decision analysis. <i>Journal of Surgical Oncology</i> , 2021, 124, 801-809.	0.8	3
67	Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement. <i>Annals of Surgery</i> , 2021, 274, 894-901.	2.1	15
68	The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 249.	7.1	131
69	Combined multiagent chemotherapy and radiotherapy is associated with prolonged overall survival in patients with non-operatively managed stage II-III pancreatic adenocarcinoma. <i>Hpb</i> , 2021, , .	0.1	2
70	Pre-Operative MDCT Staging Predicts Mesopancreatic Fat Infiltrationâ€™A Novel Marker for Neoadjuvant Treatment?. <i>Cancers</i> , 2021, 13, 4361.	1.7	5
71	Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 4724.	1.7	18
72	Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2543-2550.	0.5	8
73	Current Controversies in Neoadjuvant Therapy for Pancreatic Cancer. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 657-671.	0.6	0
74	Centralization of pancreatic cancer treatment within an integrated healthcare system improves overall survival. <i>American Journal of Surgery</i> , 2022, 223, 1035-1039.	0.9	13
75	Neoadjuvant treatment of localized pancreatic adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 0-0.	0.6	1

#	ARTICLE	IF	CITATIONS
77	Can local ablative techniques replace surgery for locally advanced pancreatic cancer?. Journal of Gastrointestinal Oncology, 2021, 12, 2536-2546.	0.6	4
79	Tumor Size Differences Between Preoperative Endoscopic Ultrasound and Postoperative Pathology for Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma Predict Patient Outcome. Clinical Gastroenterology and Hepatology, 2020, , .	2.4	5
80	Adjuvant Chemotherapy Is Not Guided by Pathologic Treatment Effect After Neoadjuvant Chemotherapy in Pancreatic Cancer. Pancreas, 2021, 50, 1163-1168.	0.5	0
81	The Role of Radiological Parameters in Assessing Response to Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer. Research in Oncology, 2020, , .	0.2	1
82	Review of Oncology and Transplant Literature for the Management of Hepatic and Pancreatic Resections in Jehovah's Witnesses. , 2021, 4, 16-26.		1
83	Dramatic Reduction of Distant Pancreatic Metastases Using Local Light Activation of Verteporfin with Nab-Paclitaxel. Cancers, 2021, 13, 5781.	1.7	2
84	Imaging Assessment of Pancreatic Cancer Resectability After Neoadjuvant Therapy: <i>AJR</i> Expert Panel Narrative Review. American Journal of Roentgenology, 2022, 218, 570-581.	1.0	11
85	Identifying Outcomes of Patients With Advanced Pancreatic Adenocarcinoma and RECIST Stable Disease Using Radiomics Analysis. JCO Precision Oncology, 2022, 6, e2100362.	1.5	1
86	Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment?. International Journal of Molecular Sciences, 2022, 23, 3620.	1.8	11
87	Neoadjuvant Treatment Lowers the Risk of Mesopancreatic Fat Infiltration and Local Recurrence in Patients with Pancreatic Cancer. Cancers, 2022, 14, 68.	1.7	2
88	Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using capecitabine-based versus gemcitabine-based concurrent chemotherapy. Journal of Gastrointestinal Oncology, 2021, 12, 2557-2566.	0.6	1
89	Prediction of Tumor-Infiltrating CD20+ B-Cells in Patients with Pancreatic Ductal Adenocarcinoma Using a Multilayer Perceptron Network Classifier Based on Non-contrast MRI. Academic Radiology, 2022, 29, e167-e177.	1.3	5
90	Stroma composition and proliferative activity are related to therapy response in neoadjuvant treated pancreatic ductal adenocarcinoma. Histology and Histopathology, 2021, 36, 733-742.	0.5	5
91	Pancreas tail adenocarcinoma tumor size is highly predictive of positive margins after a nonradical resection. American Journal of Surgery, 2022, , .	0.9	0
92	Choosing Wisely Philippines: ten low-value or harmful practices that should be avoided in cancer care. Ecancermedicallscience, 0, 16, .	0.6	1
93	Correlation of transcriptional subtypes with a validated CT radiomics score in resectable pancreatic ductal adenocarcinoma. European Radiology, 2022, 32, 6712-6722.	2.3	6
94	The Effectiveness of Chemoradiotherapy in Elderly Patients with Pancreatic Cancer: A Population-Based Study Based on the SEER Database. Advances in Therapy, 2022, 39, 5043-5057.	1.3	0
95	Neoadjuvant Chemotherapy-Chemoradiation for Borderline-Resectable Pancreatic Adenocarcinoma: A UK Tertiary Surgical Oncology Centre Series. Cancers, 2022, 14, 4678.	1.7	3

#	ARTICLE	IF	CITATIONS
96	Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis. <i>British Journal of Surgery</i> , 2022, 110, 34-42.	0.1	26
97	Improved outcomes for borderline resectable adenocarcinoma of the pancreas after neoadjuvant chemotherapy in a community cancer center. <i>American Journal of Surgery</i> , 2022, , .	0.9	0
98	Neoadjuvant chemotherapy and radiotherapy outcomes in <scp>borderlineâ€resectable</scp> and <scp>locallyâ€advanced</scp> pancreatic cancer patients. <i>Cancer Medicine</i> , 2023, 12, 7713-7723.	1.3	3
99	Neoadjuvant Treatment Versus Upfront Surgery in Resectable Pancreatic Cancer: A Cost-Effectiveness Analysis. <i>JCO Oncology Practice</i> , 2023, 19, e439-e448.	1.4	2
100	Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study. <i>MedComm</i> , 2023, 4, .	3.1	9
101	Technical options in surgery for artery-involving pancreatic cancer: Invasion depth matters. <i>Surgery Open Science</i> , 2023, 12, 55-61.	0.5	0
102	Ductal Adenocarcinoma and Pancreatic Intraepithelial Neoplasia. , 2023, , 157-220.		0
103	Neoadjuvant chemotherapy for resectable pancreatic cancer: a new standard of care?. <i>Annals of HPB Surgery</i> , 2023, 28, 80-87.	0.1	0
104	Early Recurrence after Upfront Surgery for Pancreatic Ductal Adenocarcinoma. <i>Current Oncology</i> , 2023, 30, 3708-3720.	0.9	0
105	Perineural Invasion of Pancreatic Ductal Adenocarcinoma is Associated with Early Recurrence after Neoadjuvant Therapy Followed by Resection. <i>World Journal of Surgery</i> , 2023, 47, 1801-1808.	0.8	0